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a b s t r a c t 
Genetic association studies suggest a genetic predisposi- 
tion for cisplatin-induced ototoxicity. Among other candidate 
genes, thiopurine methyltransferase ( TPMT ) is considered a 
critical gene for susceptibility to cisplatin-induced hearing 
loss in a pharmacogenetic guideline. The PanCareLIFE cross- 
sectional cohort study evaluated the genetic associations in 
a large pan-European population and assessed the diagnos- 
tic accuracy of the genetic markers. 1,112 pediatric cancer 
survivors who had provided biomaterial for genotyping were 
screened for participation in the pharmacogenetic association 
study. 900 participants qualified for inclusion. Based on the 
assessment of original audiograms, patients were assigned to 
three phenotype categories: no, minor, and clinically relevant 
hearing loss. Fourteen variants in eleven candidate genes 
( ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, 
SOD2, WFS1, and ACYP2 ) were genotyped. The genotype and 
phenotype data represent a resource for conducting meta- 
analyses to derive a more precise pooled estimate of the ef- 
fects of genes on the risk of hearing loss due to platinum 
treatment. 
© 2020 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY license. 
( http://creativecommons.org/licenses/by/4.0/ ) 







 Specifications Table 
Subject Oncology 
Specific subject area Late effects of cancer treatment; pharmacogenetics 
Type of data Table 
How data were acquired Clinical data: from servers for the electronic medical records and registries and 
by manual review of patient medical charts. 
Genotype data: Applied Biosystems 7500 FastReal-Time PCR System 
Data format Raw 
Analyzed 
Filtered 
Parameters for data collection Genotype data: Applied Biosystems 7500 Real-Time PCR System Sequence 
Detection Software v1.4, automatic genotype call algorithm. 
Description of data collection Clinical data: Data for enrolled patients from medical records were entered 
into a trial-specific database hosted at the German Childhood Cancer Registry. 
Genotype data: Genomic DNA was isolated from EDTA blood samples or saliva 
samples and tested for quality. Samples were genotyped for 14 SNPs by 
TaqMan SNP genotyping using predesigned primers and probes (Applied 
Biosystems, Foster City, CA, USA). 
Audiological Classification and Phenotype data: Patients were assigned to one 
of three phenotypes based on the grading of the audiograms according to the 
Münster Classification. 
Data source location PanCareLIFE Data Center, German Childhood Cancer Registry 
Mainz 
Germany 
Data accessibility With the article 
Related research article Thorsten Langer, Eva Clemens, Linda Broer, Lara Maier, André G. Uitterlinden, 
Andrica C. H. de Vries, Martine van Grotel, Saskia F.M. Pluijm, Harald Binder, 
Benjamin Mayer, Annika von dem Knesebeck, Julianne Byrne, Eline van 
Dulmen-den Broeder, Marco Crocco, Desiree Grabow, Peter Kaatsch, Melanie 
Kaiser, Claudia Spix, Line Kenborg, Jeanette F. Winther, Catherine Rechnitzer, 
Henrik Hasle, Tomas Kepak, Anne-Lotte F. van der Kooi, Leontien C. Kremer, 
Jarmila Kruseova, Stefan Bielack, Benjamin Sorg, Stefanie Hecker-Nolting, 
Claudia E. Kuehni, Marc Ansari, Martin Kompis, Heleen van der Pal, Ross 
Parfitt, Dirk Deuster, Peter Matulat, Amelie Tillmanns, Wim J. E. Tissing, Jörn D. 
Beck, Susanne Elsner, Antoinette am Zehnhoff-Dinnesen, Marry M. van den 
Heuvel-Eibrink, and Oliver Zolk, on behalf of the PanCareLIFE consortium 
Usefulness of current candidate genetic markers to identify childhood cancer 
patients at risk for platinum-induced ototoxicity: results of the European 
PanCareLIFE cohort study. Eur. J. Cancer. In Press. 
Value of the Data 
• This database describes genotypes of 14 candidate SNPs for cisplatin-induced ototoxicity in a
large Pan-European cohort of pediatric cancer survivors treated with platinum. 
• Epidemiologists interested in the frequency of platinum-induced ototoxicity as well as de-
velopers of long-term follow-up guidelines for survivors of childhood, adolescent, and young
adult cancers may benefit from these data. 
• The genotype and phenotype data represent a resource for conducting meta-analyses to de-
rive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to
platinum treatment. 
1. Data Description 
Table 1 summarize the genotype and allele frequencies of the study population, stratified
according to the hearing loss phenotype. 
The supplementary Table 1 shows demographic and clinical variables at a patient-level of the
total cohort (n = 900). Variables are described as follows: 
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Table 1 
Number and frequency of genotypes and alleles for each single nucleotide polymorphism (SNP) according to audiological 
phenotypes. The last column shows the P-values of the Hardy-Weinberg equilibrium (HWE) χ2 tests of the total cohort 




Number of genotypes / alleles Frequency HWE 
Chi-squared 
test P value no hearing loss 
(n = 222) 
minor hearing 
loss (n = 481) 
clinically relevant 
hearing loss (n = 197) 
Total cohort 
(n = 900) 
ABCC3 
rs1051640 
A/A 152 337 131 0.665 0.85 
A/G 64 128 61 0.310 
G/G 6 16 5 0.025 
A 368 802 323 0.820 
G 76 160 71 0.180 
ACYP2 
rs1872328 
G/G 204 453 185 0.939 0.32 
G/A 18 28 12 0.061 
A/A 0 0 0 0.0 0 0 
G 426 934 382 0.970 
A 18 28 12 0.030 
GSTP1 
rs1695 
A/A 95 221 89 0.452 0.58 
A/G 104 212 76 0.386 
G/G 23 48 32 0.162 
A 294 654 254 0.645 
G 150 308 140 0.355 
LRP2 
rs2075252 
T/T 15 32 12 0.061 0.26 
T/C 79 165 74 0.376 
C/C 128 284 111 0.563 
T 109 229 98 0.249 
C 335 733 296 0.751 
NFE2L2 
rs6721961 
T/T 2 7 3 0.015 0.82 
T/G 51 89 50 0.254 
G/G 169 385 144 0.731 
T 55 103 56 0.142 
G 389 859 338 0.858 
OTOS 
rs2291767 
T/T 215 453 188 0.954 0.55 
T/C 7 27 9 0.046 
C/C 0 1 0 0.0 0 0 
T 437 933 385 0.977 
C 7 29 9 0.023 
SLC16A5 
rs4788863 
T/T 16 37 12 0.061 0.27 
T/C 97 199 82 0.416 
C/C 109 245 103 0.523 
T 129 273 106 0.269 
C 315 689 288 0.731 
SLC22A2 
rs316019 
A/A 3 3 2 0.010 0.43 
A/C 44 85 47 0.239 
C/C 175 393 148 0.751 
A 50 91 51 0.129 
C 394 871 343 0.871 
SOD2 
rs4880 
A/A 56 106 40 0.203 0.36 
A/G 109 249 105 0.533 
G/G 57 126 52 0.264 
A 221 461 185 0.470 
G 223 501 209 0.530 
TPMT 
rs12201199 
A/A 205 434 174 0.883 0.6 
A/T 17 44 23 0.117 
T/T 0 3 0 0.0 0 0 
A 427 912 371 0.942 
T 17 50 23 0.058 
TPMT 
rs1142345 
T/T 211 452 182 0.924 0.34 
T/C 11 29 15 0.076 
C/C 0 0 0 0.0 0 0 
T 433 933 379 0.962 
C 11 29 15 0.038 
( continued on next page ) 
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Table 1 ( continued ) 
SNP Genotype/ 
allele 
Number of genotypes / alleles Frequency HWE 
Chi-squared 
test P value 
no hearing loss 
(n = 222) 
minor hearing 
loss (n = 481) 
clinically relevant 
hearing loss (n = 197) 
Total cohort 
(n = 900) 
TPMT 
rs1800460 
C/C 212 454 184 0.934 0.39 
C/T 10 27 13 0.066 
T/T 0 0 0 0.0 0 0 
C 434 935 381 0.967 
T 10 27 13 0.033 
TPMT 
rs1800462 
C/C 220 481 196 0.995 0.96 
C/G 2 0 1 0.005 
G/G 0 0 0 0.0 0 0 
C 442 962 393 0.997 
G 2 0 1 0.003 
WFS1 
rs62283056 
G/G 138 307 124 0.629 0.97 
G/C 79 149 65 0.330 
C/C 5 25 8 0.041 
G 355 763 313 0.794 








 ID – Unique identification number assigned to each patient who was included in the analyses.
RX – Cranial radiation (0) or no cranial radiation (1) 
SEX – Male (1) or female (2) 
PHENO – audiological phenotype: no hearing loss (0), minor hearing loss (1), clinically rel-
evant hearing loss (2). Patients were assigned to the respective audiological phenotype
based on the post-treatment audiograms of the patients, which were graded according
to the Münster Classification. A detailed description of the phenotyping method is given
below. 
AGE – age at start of platinum treatment: < = 5 years (1),]5 years; 10 years] (2),]10 years;
15 years] (3), > 15 years (4). 
CISPLATIN – Cumulative dose of cisplatin (mg) 
CARBOPLATIN – Cumulative dose of carboplatin (mg) 
DIAGNOSIS – the cancer diagnosis 
The supplementary Table 2 shows the genotype data at a patient-level of the total cohort
(n = 900). Variables are described as follows: 
SAMPLE_ID – Unique identification number assigned to the gDNA sample of each patient
included in the analyses. 
ABCC3_rs1051640 – the rs1051640 genotype: A/A (0), A/G (1), G/G (2) 
OTOS_rs2291767 – the rs2291767 genotype: T/T (0), T/C (1), C/C (2) 
TPMT_rs12201199 – the rs12201199 genotype: A/A (0), A/T (1), T/T (2) 
TPMT_rs1142345 – the rs1142345 genotype: T/T (0), T/C (1), C/C (2) 
TPMT_rs1800460 – the rs1800460 genotype: C/C (0), C/T (1), T/T (2) 
TPMT_rs1800462 – the rs1800462 genotype: C/C (0), C/G (1), G/G (2) 
SLC22A2_rs316019 – the rs316019 genotype: A/A (0), A/C (1), C/C (2) 
NFE2L2_rs6721961 – the rs6721961 genotype: T/T (0), T/G (1), G/G (2) 
WFS1_rs62283056 – the rs62283056 genotype: G/G (0), G/C (1), C/C (2) 
SLC16A5_rs4788863 –the rs4788863 genotype: T/T (0), T/C (1), C/C (2) 
LRP2_rs2075252 – the rs2075252 genotype: T/T (0), T/C (1), C/C (2) 
GSTP1_rs1695 – the rs1695 genotype: A/A (0), A/G (1), G/G (2) 
SOD2_rs4880 – the rs4880 genotype: A/A (0), A/G (1), G/G (2) 
ACYP2_rs1872328 – the rs1872328 genotype: G/G (0), G/A (1), A/A (2) 













































s  . Experimental Design, Materials and Methods 
.1. Study design and participants 
Background and methods of the European multicenter PanCareLIFE study have been de-
cribed previously [1–3] . Patients were enrolled after approval was obtained from local review
oards and written informed consent was obtained from patients, parents or legal guardians.
articipants were enrolled both retrospectively and prospectively (i.e., chemotherapy was started
nd finished during the 5-year term of PanCareLIFE). Eligibility criteria were: 1) age at diagnosis
 19 years, 2) treatment with cisplatin, carboplatin or both, 3) at least one pure tone audiome-
ry within 5 years after the end of chemotherapy. Exclusion criteria were: 1) non-consent and 2)
earing loss before the start of platinum treatment. Patients of this larger ototoxicity cohort par-
icipated in the pharmacogenetic study if there was additional consent for the genetic analyses
nd biomaterial was provided. 
.2. Genotyping 
Biosamples were sent to the PanCareLIFE genotyping center. Genomic DNA (gDNA) was iso-
ated from EDTA blood samples with a QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) or
rom saliva samples (Oragene DNA collection kit, DNA Genotec, Ottawa, ON, Canada) using
he prepIT L2P reagent (DNA Genotec, Ottawa, ON, Canada). All gDNA samples isolated were
ested for quality (A260/A280 ratio of > 1.9 and agarose gele electrophoresis) before any fur-
her work on DNA analysis. Samples were genotyped for 14 SNPs by TaqMan SNP genotyp-
ng using predesigned primers and probes (Applied Biosystems, Foster City, CA, USA). In or-
er not to lose too much statistical power, the number of candidate genes was limited to 11
ith one SNP each except for TPMT, for which 4 SNPs were examined. The candidate SNPs
ere selected on the basis of the available evidence of association, taking into account the
ample size of the discovery cohort and the effect size. The following SNPs were investi-
ated: rs1872328 ( ACYP2 ), rs2075252 ( LRP2 ), rs6721961 ( NFE2L2 ), rs2291767 ( OTOS ), rs62283056
 WFS1 ), rs12201199 ( TPMT ), rs1142345 ( TPMT ), rs1800460 ( TPMT ), rs1800462 ( TPMT ), rs4880
 SOD2 ), rs316019 ( SLC22A2 ), rs1695 ( GSTP1 ), rs1051640 ( ABCC3 ), and rs4788863 ( SLC16A5 ). 
Laboratory assistants were blinded to the audiological phenotype of the patients. Multiple
ositive and negative controls and replicate samples were included in the genotyping assays and
lates. No genotype discordance of replicate samples was observed. Ten samples were finally
xcluded due to genotype call rate per sample < 100%. 
.3. Audiological classification and phenotyping 
All audiograms were independently rated by two reviewers for hearing loss according to the
ünster classification [ 4 , 5 ]. Audiograms had to meet the following minimum requirements: fre-
uencies include at least 2 or 3 kHz, 4 kHz, and 6 or 8 kHz (air-conduction), demonstrate no
onductive hearing loss, absence of significant test artifacts (e.g., atypical air-bone configuration).
Thereafter, two pediatric audiologists independently assessed the kinetic course of hear-
ng loss for each patient. The minimum data requirement for phenotype assessment included
he availability of a normal pre-treatment audiogram or a normal audiogram before the third
latinum cycle and at least one post-treatment audiogram within 15 months after the last
hemotherapy cycle. Sound field audiometry was also accepted if ear-specific pure-tone audiom-
try was subsequently performed. Three phenotype groups were defined as follows: no hearing
oss, minor hearing loss, and clinically-relevant hearing loss at the end of treatment. Patients
ere assigned to the no hearing loss group if post-treatment audiograms were exclusively Mün-
ter class 0. Patients were also assigned to the group without hearing loss if post-treatment

























 audiograms were almost exclusively graded as Münster class 0, no audiogram was classified as
Münster > 1, and the Münster class 1 audiogram was followed by a Münster class 0 audiogram.
Patients were assigned to the clinically-relevant hearing loss group if follow-up audiograms in-
dicated hearing loss of at least Münster class 2b. All other patients were classified as part of the
minor hearing loss group. Inter-rater agreement was > 95%. After completion, all cases that had
been phenotyped differently by the two pediatric audiologists were discussed between them and
an agreement was made. 
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